{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:50:23Z","timestamp":1791514223406,"version":"4.3.4"},"reference-count":68,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Older adults with newly diagnosed acute myeloid leukemia (AML) are often ineligible for conventional \u201c7+3\u201d induction chemotherapy. Despite recent drug approvals, treatment outcomes remain poor in this population. We conducted an updated systematic review to inform the 2025 American Society of Hematology (ASH) AML update guidelines in older adults. This review compared the efficacy and safety of low-dose cytarabine (LDAC), azacitidine (AZA), 5- and 10-day decitabine (DEC), and gemtuzumab ozogamicin, alone or combined with drugs such as venetoclax (VEN), in older adults with AML ineligible for conventional chemotherapy. We included randomized controlled trials (RCTs) and nonrandomized studies (NRSs) of adults aged \u226555 years with AML, and synthesized evidence on mortality, remission, quality of life (QoL), functional status, and severe toxicity. We applied GRADE (grading of recommendations assessment, development, and evaluation) to assess the certainty of evidence. We included 47 studies (30 RCTs and 17 NRSs). AZA or LDAC combined with VEN probably reduces mortality and improves remission and QoL. AZA plus isocitrate dehydrogenase 1 (IDH1) inhibitors may reduce 1-year mortality and improve remission and survival in patients with IDH1-mutated AML. Compared with DEC alone, combining DEC with other agents showed inconsistent effects with mostly low certainty of conclusions. VEN combinations showed promising effects on mortality and remission but lacked data on QoL and functional status. In older adults with AML ineligible for conventional therapy, evidence suggests that hypomethylating agents or LDAC combined with VEN likely improves survival and remission outcomes. Treatment decisions should consider patient goals and functional status. These findings informed 8 recommendations in updated ASH-AML guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016879","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T17:06:50Z","timestamp":1768496810000},"page":"4082-4093","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-6844","authenticated-orcid":false,"given":"Maria Jose","family":"Oliveros","sequence":"first","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"2Departamento de Ciencias de la Rehabilitaci\u00f3n, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-0792","authenticated-orcid":false,"given":"Saifur R.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"3Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4564-5973","authenticated-orcid":false,"given":"Yetiani","family":"Roldan","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7713-6171","authenticated-orcid":false,"given":"Sara","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-3975","authenticated-orcid":false,"given":"Gonzalo","family":"Bravo-Soto","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"4Michael G. DeGroote National Pain Center, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Foucar","sequence":"additional","affiliation":[{"name":"5University of New Mexico Comprehensive Cancer Center, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6399-936X","authenticated-orcid":false,"given":"Gurleen","family":"Bhogal","sequence":"additional","affiliation":[{"name":"6Faculty of Dentistry, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-5491","authenticated-orcid":false,"given":"Barbara","family":"Burgos-Mansilla","sequence":"additional","affiliation":[{"name":"2Departamento de Ciencias de la Rehabilitaci\u00f3n, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-4948","authenticated-orcid":false,"given":"Mobina","family":"Bagherianlemraski","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Movahed","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvistay","family":"Gutierrez-Arias","sequence":"additional","affiliation":[{"name":"7Departamento de Apoyo en Rehabilitaci\u00f3n Cardiopulmonar Integral, Instituto Nacional del T\u00f3rax, Santiago, Chile"},{"name":"8INTRehab Research Group, Instituto Nacional del T\u00f3rax, Santiago, Chile"},{"name":"9Exercise and Rehabilitation Sciences Institute, Faculty of Rehabilitation Sciences, Universidad Andres Bello, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanin","family":"Khorrami Taj","sequence":"additional","affiliation":[{"name":"10School of Interdisciplinary Science, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Chang","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-971X","authenticated-orcid":false,"given":"Seyed Kaveh","family":"Hadeiy","sequence":"additional","affiliation":[{"name":"11Emergency Department, Bahari Hospital, Hamedan University of Medical Sciences, Hamedan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-2845","authenticated-orcid":false,"given":"Rachel","family":"Couban","sequence":"additional","affiliation":[{"name":"12Department of Anesthesia, McMaster University, Hamilton, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-7397","authenticated-orcid":false,"given":"Roberta","family":"Demichelis-Gomez","sequence":"additional","affiliation":[{"name":"13Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-1611","authenticated-orcid":false,"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"14Department of Molecular Medicine, University of Pavia and S. Matteo University Hospital Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"16Department of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gilberto","sequence":"additional","affiliation":[{"name":"17Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Treitz","sequence":"additional","affiliation":[{"name":"18Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"19University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-8948","authenticated-orcid":false,"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[{"name":"20University of Michigan College of Pharmacy, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Mattison","sequence":"additional","affiliation":[{"name":"21Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"22Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-9900","authenticated-orcid":false,"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"2","key":"2026060911214823200_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/aac2.12065","article-title":"Acute myeloid leukemia in elderly patients: new targets, new therapies","volume":"4","author":"Park","year":"2023","journal-title":"Aging Cancer"},{"issue":"7","key":"2026060911214823200_bib2","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S2352-3026(22)00167-3","article-title":"Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia","volume":"9","author":"Short","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026060911214823200_bib3","doi-asserted-by":"crossref","first-page":"102549","DOI":"10.1016\/j.eclinm.2024.102549","article-title":"Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001\u20132019","volume":"71","author":"Linet","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2026060911214823200_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026060911214823200_bib5","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/bloodadvances.2024013304","article-title":"Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia","volume":"9","author":"Ruhnke","year":"2025","journal-title":"Blood Adv"},{"issue":"15","key":"2026060911214823200_bib6","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2026060911214823200_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2026060911214823200_bib8","doi-asserted-by":"crossref","first-page":"E914","DOI":"10.1097\/HS9.0000000000000914","article-title":"An overview of targeted therapies in acute myeloid leukemia","volume":"7","author":"Turkalj","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"2026060911214823200_bib9","doi-asserted-by":"crossref","first-page":"e0263240","DOI":"10.1371\/journal.pone.0263240","article-title":"Less intensive antileukemic therapies (monotherapy and\/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: a systematic review and metaanalysis","volume":"17","author":"Colunga-Lozano","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"2026060911214823200_bib69","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2025017934","article-title":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"10","author":"Sekeres","year":"2026","journal-title":"Blood Adv"},{"issue":"10","key":"2026060911214823200_bib10","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/bloodadvances.2020001768","article-title":"Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences","volume":"4","author":"Wiercioch","year":"2020","journal-title":"Blood Adv"},{"key":"2026060911214823200_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026060911214823200_bib12","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026060911214823200_bib13","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7650","key":"2026060911214823200_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026060911214823200_bib15","doi-asserted-by":"crossref","first-page":"e081903","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the Core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026060911214823200_bib16","doi-asserted-by":"crossref","first-page":"e081904","DOI":"10.1136\/bmj-2024-081904","article-title":"Core GRADE 2: choosing the target of certainty rating and assessing imprecision","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026060911214823200_bib17","doi-asserted-by":"crossref","first-page":"e083864","DOI":"10.1136\/bmj-2024-083864","article-title":"Core GRADE 4: rating certainty of evidence-risk of bias, publication bias, and reasons for rating up certainty","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"2026060911214823200_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2026060911214823200_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2026060911214823200_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/10428194.2022.2148212","article-title":"A randomized phase II\/III study of \u2018novel therapeutics\u2019 versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612","volume":"64","author":"Assouline","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026060911214823200_bib21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2011.59","article-title":"The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome","volume":"25","author":"Burnett","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2026060911214823200_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2026060911214823200_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjh.19220","article-title":"A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: results from the LI-1 trial","volume":"204","author":"Copland","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"2026060911214823200_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2026060911214823200_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.17501","article-title":"A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial","volume":"194","author":"Dennis","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"2026060911214823200_bib26","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1182\/bloodadvances.2021005038","article-title":"Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients","volume":"5","author":"Dennis","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2026060911214823200_bib27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026060911214823200_bib28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"Dohner","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026060911214823200_bib29","doi-asserted-by":"crossref","first-page":"E617","DOI":"10.1097\/HS9.0000000000000617","article-title":"Adjunctive volasertib in patients with acute myeloid leukemia not eligible for standard induction therapy: a randomized, phase 3 trial","volume":"5","author":"Dohner","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"2026060911214823200_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026060911214823200_bib31","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2026060911214823200_bib32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3324\/haematol.2018.201152","article-title":"Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia","volume":"104","author":"Kenealy","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2026060911214823200_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 x 2, phase II trial","volume":"38","author":"Lubbert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026060911214823200_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.2017.172353","article-title":"Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia","volume":"103","author":"Medeiros","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2026060911214823200_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/leu.2016.303","article-title":"A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials","volume":"31","author":"Montalban-Bravo","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"2026060911214823200_bib36","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060911214823200_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2026060911214823200_bib38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.18560","article-title":"A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: results from the LI-1 trial","volume":"200","author":"Mussai","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"2026060911214823200_bib39","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026060911214823200_bib40","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine \u00b1 bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2026060911214823200_bib41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"2026060911214823200_bib42","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026060911214823200_bib43","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol"},{"issue":"12","key":"2026060911214823200_bib44","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/cncr.33403","article-title":"A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia","volume":"127","author":"Vives","year":"2021","journal-title":"Cancer"},{"issue":"17","key":"2026060911214823200_bib45","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2026060911214823200_bib46","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2026060911214823200_bib47","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2026060911214823200_bib48","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"2026060911214823200_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-021-00435-1","article-title":"Mayo Clinic experience with 1123 adults with acute myeloid leukemia","volume":"11","author":"Begna","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026060911214823200_bib50","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.26941","article-title":"Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion","volume":"98","author":"Daver","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2026060911214823200_bib51","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026060911214823200_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2026060911214823200_bib53","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.26724","article-title":"Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia","volume":"97","author":"Venugopal","year":"2022","journal-title":"Am J Hematol"},{"key":"2026060911214823200_bib54","doi-asserted-by":"crossref","first-page":"858202","DOI":"10.3389\/fonc.2022.858202","article-title":"Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a propensity score-adjusted cohort study","volume":"12","author":"Mustafa Ali","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"2026060911214823200_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jha2.663","article-title":"Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia","volume":"4","author":"Bouligny","year":"2023","journal-title":"EJHaem"},{"issue":"4","key":"2026060911214823200_bib56","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.26846","article-title":"Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with venetoclax","volume":"98","author":"Candoni","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2026060911214823200_bib57","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/1120009X.2022.2097433","article-title":"Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience","volume":"35","author":"Chen","year":"2023","journal-title":"J Chemother"},{"key":"2026060911214823200_bib58","doi-asserted-by":"crossref","first-page":"106803","DOI":"10.1016\/j.leukres.2022.106803","article-title":"Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience","volume":"114","author":"De Bellis","year":"2022","journal-title":"Leuk Res"},{"issue":"1","key":"2026060911214823200_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2026060911214823200_bib60","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026060911214823200_bib61","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","article-title":"Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting","volume":"23","author":"Gershon","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"2026060911214823200_bib62","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2026060911214823200_bib63","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2022-171105","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score matched analysis","volume":"140","author":"Kwag","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026060911214823200_bib64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J"},{"issue":"24","key":"2026060911214823200_bib66","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood.2024026004","article-title":"The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment","volume":"145","author":"Abedin","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026060911214823200_bib67","first-page":"280-16","article-title":"Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis","volume":"30","author":"Li","year":"2025","journal-title":"Eur J Med Res"},{"issue":"6","key":"2026060911214823200_bib68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bmjebm-2022-112185","article-title":"Rapid reviews methods series: guidance on team considerations, study selection, data extraction and risk of bias assessment","volume":"28","author":"Nussbaumer-Streit","year":"2023","journal-title":"BMJ Evid Based Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4082\/2525571\/blooda_adv-2025-016879-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4082\/2525571\/blooda_adv-2025-016879-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:22:23Z","timestamp":1781018543000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/4082\/566015\/Antileukemic-therapies-for-older-adults-with-AML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016879","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,6,9]]}}}